Li Zhang1, Hui Du1, Tai-wu Xiao2, Ji-zhu Liu2, Guo-zhen Liu2, Jing-xia Wang2, Guang-yao Li3, Le-xin Wang4. 1. Medicine school of Shandong University, Jinan, Shandong 250012, PR China; Division of Hematology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, PR China. 2. Medicine school of Shandong University, Jinan, Shandong 250012, PR China. 3. Medicine school of Shandong University, Jinan, Shandong 250012, PR China; Division of Hematology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, PR China. Electronic address: lcrmyy@163.com. 4. School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales 2650, Australia. Electronic address: lwang@csu.edu.au.
Abstract
OBJECTIVE: To investigate the expression of PD-1 and TIM-3 in CD3+ T cells in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A retrospective analysis was conducted on data from 46 patients with newly diagnosed DLBCL and 30 healthy people. Flow cytometry was used to detect the expression of PD-1 and TIM-3 before and after chemotherapy. RESULTS: Compared to healthy control, the expression of PD-1 and TIM-3 in patients with DLBCL was increased in CD3+ T cells. There is no significant change of PD-1 and TIM-3 in patients with stage I/II DLBCL, however, they were markedly increased in patients with stage III/IV DLBCL. The expression of PD-1 and TIM-3 elevated in DLBCL patients with B symptoms, IPI score >2 points and high level of LDH and Ki-67. After four courses of standard chemotherapy, PD-1 and TIM-3 expression level decreased. The treatment efficiency is higher in patients with low expression of PD-1 and TIM-3 than in patients with high PD-1 and TIM-3 expression. CONCLUSION: DLBCL patients have high expression level of PD-1 and TIM-3, which are related to DLBCL staging. PD-1 and TIM-3 expression levels are also related to the efficiency of chemotherapy. PD-1 and TIM-3 expression levels may be used as an indicator of chemotherapeutic efficacy in patients with DLBCL.
OBJECTIVE: To investigate the expression of PD-1 and TIM-3 in CD3+ T cells in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A retrospective analysis was conducted on data from 46 patients with newly diagnosed DLBCL and 30 healthy people. Flow cytometry was used to detect the expression of PD-1 and TIM-3 before and after chemotherapy. RESULTS: Compared to healthy control, the expression of PD-1 and TIM-3 in patients with DLBCL was increased in CD3+ T cells. There is no significant change of PD-1 and TIM-3 in patients with stage I/II DLBCL, however, they were markedly increased in patients with stage III/IV DLBCL. The expression of PD-1 and TIM-3 elevated in DLBCL patients with B symptoms, IPI score >2 points and high level of LDH and Ki-67. After four courses of standard chemotherapy, PD-1 and TIM-3 expression level decreased. The treatment efficiency is higher in patients with low expression of PD-1 and TIM-3 than in patients with high PD-1 and TIM-3 expression. CONCLUSION: DLBCL patients have high expression level of PD-1 and TIM-3, which are related to DLBCL staging. PD-1 and TIM-3 expression levels are also related to the efficiency of chemotherapy. PD-1 and TIM-3 expression levels may be used as an indicator of chemotherapeutic efficacy in patients with DLBCL.
Authors: Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits Journal: Oncoimmunology Date: 2016-11-28 Impact factor: 8.110
Authors: Elly Marcq; Jonas Rm Van Audenaerde; Jorrit De Waele; Julie Jacobs; Jinthe Van Loenhout; Glenn Cavents; Patrick Pauwels; Jan P van Meerbeeck; Evelien Lj Smits Journal: Int J Mol Sci Date: 2019-08-26 Impact factor: 5.923